Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
NCT05003921Phase 1Withdrawn
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Dec 2025
- Primary completion
- Sep 2028
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial in amyotrophic lateral sclerosis (ALS), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Safety (adverse events) at 4 years. Planned start Dec 2025; status: withdrawn.
02
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05003921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003921.